Identification of a human heavy chain antibody fragment directed against human platelet alloantigen la by phage display library |
| |
Authors: | N. Okamoto S.D. Kennedy E.A. Barron-Casella J.R. Casella H. Inoko T.S. Kickler |
| |
Affiliation: | Biomédical Research Center, Olympus Optical Co. Ltd. 2–3 Kuboyamacho, Hachiojishi, Tokyo, Japan;Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.;Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.;Department of Genetic Information, Division of Molecular Life Science, Tokai University of Medicine, Bohseidai, Isehara, Kanagawa, Japan |
| |
Abstract: | Abstract: The human platelet alloantigen HPA-la (PlA1) is responsible for most cases of post-transfusion purpura and neonatal alloimmune thrombo-cytopenia in the Caucasian population. HPA-la and HPA-lb are two allelic forms of the platelet membrane glycoprotein IIIa (GPIIIa) gene that differ by a single amino acid. In this report, we describe the development of a recom-binant heavy chain antibody fragment capable of distinguishing between the homozygous forms of HPA-la and HPA-lb. This antibody fragment was isolated from the lymphocytes of an immunized individual through the use of a phage display library system. The recombinant antibody fragment reacted with human platelet lysates from HPA-la homozygous donors, the HPA-la form of recombinant N-terminal GPIIIa and intact HPA-la platelets, but did not react with platelet lysate from HPA-1b homozygous donors, reduced HPA-la form of platelet GPIIIa or other platelet glycoproteins. This HPA-la specific human antibody fragment works well in common laboratory assays such as ELISA and flow cytometry, which can assist in identifying HPA-lb homozygous individuals who are known to have a higher risk for developing neonatal alloimmmune thrombocytopenia and post-transfusion purpura. Thus, selection of recombinant antibody fragment using phage display offers a promising alternative to hybridoma technology for the production of human antibodies against human alloantigens and holds potential as a technique in therapeutic applications. |
| |
Keywords: | glycoprotein Ilia human platelet alloantigen phage display library recombinant antibody |
|
|